Lesi A, Meremikwu M
Department of Paediatrics, College of Medicine, University of Lagos, Lagos, Nigeria.
Cochrane Database Syst Rev. 2004;2004(3):CD003341. doi: 10.1002/14651858.CD003341.pub2.
Quinine is used for treating severe malaria. There are arguments for giving an initial high dose. We examined the evidence for and against this policy.
To assess the clinical outcomes and adverse events of a high first (loading) dose regimen of quinine compared with a uniform (no loading) dose regimen in people with severe malaria.
We searched the Cochrane Infectious Diseases Group's trials register (April 2004), CENTRAL (The Cochrane Library Issue 1, 2004), MEDLINE (1966 to April 2004), EMBASE (1974 to April 2004), LILACS (1982 to April 2004), and conference proceedings for relevant abstracts. We also contacted researchers working in the field and checked the reference lists of all studies.
Randomized controlled trials comparing a high first (loading) dose of intravenous quinine with a uniform (no loading) dose of intravenous quinine in people with severe malaria.
Two reviewers independently assessed the methodological quality of the trials and extracted data (including adverse event data). We used Review Manager 4.2 to analyse the data: relative risk (RR) for binary data and weighted mean difference (WMD) for continuous data with 95% confidence intervals (CI). We contacted study authors for additional information.
Four trials (n = 144) met the inclusion criteria. Loading dose was associated with fewer deaths, but this was not statistically significant (RR 0.62, CI 0.19 to 2.04, 3 trials). Loading dose was associated with faster clearance of parasites (WMD -7.44 hours, CI -13.24 to -1.64 hours, 2 trials), resolution of fever (WMD -11.11 hours, CI -20.04 to -2.18 hours, 2 trials). No statistically significant difference was detected for recovery of consciousness, neurological sequelae, or convulsions, but the numbers were small.
REVIEWERS' CONCLUSIONS: Quinine loading dose reduced fever clearance time and parasite clearance time. Data are insufficient to directly demonstrate an impact of loading dose on risk of death.
奎宁用于治疗重症疟疾。对于给予初始高剂量存在争议。我们审查了支持和反对该政策的证据。
评估重症疟疾患者中,与统一(无负荷)剂量方案相比,奎宁高首剂(负荷)剂量方案的临床结局和不良事件。
我们检索了Cochrane传染病组试验注册库(2004年4月)、CENTRAL(Cochrane图书馆2004年第1期)、MEDLINE(1966年至2004年4月)、EMBASE(1974年至2004年4月)、LILACS(1982年至2004年4月)以及会议论文集以查找相关摘要。我们还联系了该领域的研究人员并查阅了所有研究的参考文献列表。
比较重症疟疾患者中高首剂(负荷)静脉注射奎宁与统一(无负荷)静脉注射奎宁剂量的随机对照试验。
两名评价员独立评估试验的方法学质量并提取数据(包括不良事件数据)。我们使用Review Manager 4.2分析数据:二分类数据的相对危险度(RR)和连续数据的加权均数差(WMD),并给出95%置信区间(CI)。我们联系研究作者获取更多信息。
四项试验(n = 144)符合纳入标准。负荷剂量与死亡人数减少相关,但无统计学意义(RR 0.62,CI 0.19至2.04,3项试验)。负荷剂量与寄生虫清除更快相关(WMD -7.44小时,CI -13.24至 -1.64小时,2项试验),发热消退更快相关(WMD -11.11小时,CI -20.04至 -2.18小时,2项试验)。在意识恢复、神经后遗症或惊厥方面未检测到统计学显著差异,但样本量较小。
奎宁负荷剂量缩短了发热清除时间和寄生虫清除时间。数据不足以直接证明负荷剂量对死亡风险的影响。